Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Eagle Ridge Investment Management

Eagle Ridge Investment Management grew its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 195,186 shares of the medical equipment provider’s stock after buying an additional 3,726 shares during the quarter. Eagle Ridge Investment Management owned 0.08% of Hologic worth $15,900,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Wolff Wiese Magana LLC acquired a new position in Hologic during the third quarter worth about $25,000. Innealta Capital LLC acquired a new position in Hologic during the second quarter worth $25,000. iA Global Asset Management Inc. purchased a new stake in Hologic during the first quarter worth $37,000. Sunbelt Securities Inc. acquired a new stake in Hologic in the second quarter valued at $37,000. Finally, Cranbrook Wealth Management LLC purchased a new position in Hologic during the 2nd quarter valued at about $47,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Buying and Selling at Hologic

In other Hologic news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.75% of the stock is owned by insiders.

Hologic Trading Down 0.5 %

Shares of HOLX opened at $80.91 on Friday. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67. The stock has a 50-day moving average price of $80.94 and a 200 day moving average price of $77.84. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The company has a market capitalization of $18.88 billion, a P/E ratio of 41.28, a P/E/G ratio of 2.89 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period last year, the business earned $0.93 EPS. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. Sell-side analysts forecast that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the subject of a number of analyst reports. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and cut their price target for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Leerink Partners lowered their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Evercore ISI increased their target price on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. StockNews.com cut Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research report on Friday, August 16th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $87.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.